Google
GLMD — GALMED PHARMACEUTICALS LTD (Healthcare >> Biotechnology)
GLMD FAQ
What is GLMD's ROE?
GALMED PHARMACEUTICALS LTD reports a Return on Equity (ROE) of -65.32%.
What is GLMD's dividend yield?
GALMED PHARMACEUTICALS LTD offers a dividend yield of 0.00%.
What is GLMD's Deepscope Quality Score?
Deepscope rates GLMD's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GLMD?
Deepscope's AI Timing Score for GLMD is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GLMD belong to?
GALMED PHARMACEUTICALS LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.70
Price
-0.03
(-4.67%)
Day Change
|
|
|---|
GLMD, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.70 |
| PBV / Sector |
0.29 / 4.63
GREAT
|
| Earning Per Share | -2.39 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.09 M
GREAT
|
| Average 1W Daily Value |
0.09 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:26 |
| Symbol | GLMD |
| Name | GALMED PHARMACEUTICALS LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 6.60 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4.58 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 16 Abba Hillel Road, Ramat Gan, Israel, 5250608
Phone: 972 3 693 8448
Website: https://galmedpharma.com
Sector: Healthcare >> Biotechnology
Description: Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
